89483-06-7

Usage

Chemical Properties

White powder

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 102735-53-5 (2S)-2-amino-3-cyclopropylpropanoic acid 
• 104347-84-4 methyl (S)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoate 

Downstream Products

• 905927-61-9 {2-[3-(2-tert-butoxycarbonylamino-3-cyclopropyl-propionylamino)-4-cyclopropyl-2-hydroxy-butyrylamino]-acetylamino}-phenyl-acetic acid tert-butyl ester 
• 1401624-94-9 tert-butyl (S)-1-((1R,2R)-1-carbamoyl-2-(4'-(4-methylpiperazin-1-yl-sulfonyl)biphenyl-4-yl)cyclopropylamino)-3-cyclopropyl-oxopropan-2-ylcarbamate 
• 1401624-95-0 tert-butyl (S)-1-((1S,2S)-1-carbamoyl-2-(4'-(4-methylpiperazin-1-yl-sulfonyl)biphenyl-4-yl)cyclopropylamino)-3-cyclopropyl-oxopropan-2-ylcarbamate 
• 1401624-96-1 tert-butyl (S)-1-((1R,2R)-1-cyano-2-(4'-(4-methylpiperazin-1-ylsulfonyl)biphenyl-4-yl)cyclopropylamino)-3-cyclopropyl-1-oxopropan-2-ylcarbamate 
• 1401624-97-2 tert-butyl (S)-1-((1S,2S)-1-cyano-2-(4'-(4-methylpiperazin-1-ylsulfonyl)biphenyl-4-yl)cyclopropylamino)-3-cyclopropyl-1-oxopropan-2-ylcarbamate 
• 1401624-34-7 (S)-2-amino-N-((1R,2R)-1-cyano-2-(4'-(4-methylpiperazin-1-ylsulfonyl)biphenyl-4-yl)cyclopropyl)-3-cyclopropylpropanamide 
• 1401624-35-8 (S)-2-amino-N-((1S,2S)-1-cyano-2-(4'-(4-methylpiperazin-1-ylsulfonyl)biphenyl-4-yl)cyclopropyl)-3-cyclopropylpropanamide 
• 1401624-92-7 (1R,2R)-methyl 1-((S)-2-(tert-butoxycarbonylamino)-3-cyclopropyl-propanamido)-2-(4'-(4-methylpiperazin-1-ylsulfonyl)biphenyl-4-yl)cyclopropanecarboxylate 
• 1401624-93-8 (1S,2S)-methyl 1-((S)-2-(tert-butoxycarbonylamino)-3-cyclopropyl-propanamido)-2-(4'-(4-methylpiperazin-1-ylsulfonyl)biphenyl-4-yl)cyclopropanecarboxylate 
• 881902-45-0 (4S,5S)-5-{3-[(S)-2-({[((S)-tert-Butoxycarbonyl-phenyl-methyl)-carbamoyl]-methyl}-carbamoyl)-1-cyclopropylmethyl-2-hydroxy-ethyl]-1-cyclopropylmethyl-ureidomethyl}-4-cyclohexyl-2,2-dimethyl-oxazolidine-3-carboxylic acid isobutyl ester 
• 905929-83-1 (S)-[2-((S)-3-{(S)-2-[((S)-2-Cyclohexyl-2-isobutoxycarbonylamino-acetyl)-methyl-amino]-3-cyclopropyl-propionylamino}-4-cyclopropyl-2-hydroxy-butyrylamino)-acetylamino]-phenyl-acetic acid tert-butyl ester 
• 905928-76-9 (4S,5S)-5-{3-[2-({[((S)-tert-Butoxycarbonyl-phenyl-methyl)-carbamoyl]-methyl}-carbamoyl)-1-cyclopropylmethyl-2-oxo-ethyl]-1-cyclopropylmethyl-ureidomethyl}-4-cyclohexyl-2,2-dimethyl-oxazolidine-3-carboxylic acid isobutyl ester 
• 905929-87-5 (S)-[2-(3-{(S)-2-[((S)-2-Cyclohexyl-2-isobutoxycarbonylamino-acetyl)-methyl-amino]-3-cyclopropyl-propionylamino}-4-cyclopropyl-2-oxo-butyrylamino)-acetylamino]-phenyl-acetic acid tert-butyl ester 
• 881902-46-1 (S)-(2-{3-[3-((S)-3-Cyclohexyl-3-isobutoxycarbonylamino-2-oxo-propyl)-3-cyclopropylmethyl-ureido]-4-cyclopropyl-2-oxo-butyrylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 

Relevant academic research and scientific papers

Inhibitors of cysteine proteases and methods of use thereof

The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease. Exemplary compounds provided include Formula II-I, where R3, RB are provided herein:

Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation

The discovery of natural specialized pro-resolving mediators and their corresponding receptors, such as formyl peptide receptor 2 (FPR2), indicated that resolution of inflammation (RoI) is an active process which could be harnessed for innovative approaches to tame pathologies with underlying chronic inflammation. In this work, homology modelling, molecular docking and pharmacophore studies were deployed to assist the rationalization of the structure-activity relationships of known FPR2 agonists. The developed pharmacophore hypothesis was then used in parallel with the homology model for the design of novel ligand structures and in virtual screening. In the first round of optimization compound 8, with a cyclopentane core, was chosen as the most promising agonist (β-arrestin recruitment EC50 = 20 nM and calcium mobilization EC50 = 740 nM). In a human neutrophil static adhesion assay, compound 8 decreased the number of adherent neutrophils in a concentration dependent manner. Further investigation led to the more rigid cycloleucines (compound 22 and 24) with improved ADME profiles and maintaining FPR2 activity. Overall, we identified novel cyclopentane urea FPR2 agonists with promising ADMET profiles and the ability to suppress the inflammatory process by inhibiting the neutrophil adhesion cascade, which indicates their anti-inflammatory and pro-resolving properties.

ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS

The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used for combating parasites in or on animals including mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in animals, including birds and mammals.

Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily

The present invention relates to compounds and pharmaceutical compositions which inhibit proteases, such as cysteine proteases. In particular, the present invention relates to compounds and pharmaceutical compositions which inhibit cysteine proteases of the papain superfamily. The compounds and pharmaceutical compositions of the present invention are useful for treating diseases, particularly parasitic diseases, which are mediated by such proteases. In particular, the present invention relates to a method of treating malaria by inhibiting the cysteine protease falcipain.

Protease inhibitors

The present invention provides compounds of formula (I) which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia or malignancy; and metabolic bone disease therewith.